Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732278 | SCV000860210 | uncertain significance | not provided | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855769 | SCV002188422 | uncertain significance | RASopathy | 2023-05-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 946 of the SOS1 protein (p.Glu946Gln). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SOS1 protein function. ClinVar contains an entry for this variant (Variation ID: 596437). This variant has not been reported in the literature in individuals affected with SOS1-related conditions. This variant is not present in population databases (gnomAD no frequency). |
Genome- |
RCV002468030 | SCV002763261 | uncertain significance | Noonan syndrome 4 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV002468029 | SCV002763262 | uncertain significance | Fibromatosis, gingival, 1 | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV003165984 | SCV003863136 | uncertain significance | Cardiovascular phenotype | 2022-12-31 | criteria provided, single submitter | clinical testing | The p.E946Q variant (also known as c.2836G>C), located in coding exon 18 of the SOS1 gene, results from a G to C substitution at nucleotide position 2836. The glutamic acid at codon 946 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |